

校编码: 10384

分类号 _____ 密级 _____

学号: 21620060153318

UDC _____

厦 门 大 学

博 士 学 位 论 文

胆管癌药物的筛选及作用机理的研究

Studies on the Screening of Cholangiocarcinoma Drugs and the Mechanisms

韩 鹏

指导教师姓名: 陈清西 教授

专业名称: 生物化学与分子生物学

论文提交日期: 2009 年 4 月 29 日

论文答辩时间: 2009 年 5 月 29 日

学位授予日期: 2009 年 月 日

答辩委员会主席: 杨叔禹 教授

评 阅 人: _____

2009 年 5 月

厦门大学博硕士学位论文摘要库

厦门大学学位论文原创性声明

本人呈交的学位论文是本人在导师指导下,独立完成的研究成果。本人在论文写作中参考其他个人或集体已经发表的研究成果,均在文中以适当方式明确标明,并符合法律规范和《厦门大学研究生学术活动规范(试行)》。

另外,该学位论文为()课题(组)的研究成果,获得()课题(组)经费或实验室的资助,在()实验室完成。(请在以上括号内填写课题或课题组负责人或实验室名称,未有此项声明内容的,可以不作特别声明。)

声明人(签名):

年 月 日

厦门大学博硕士学位论文摘要库

厦门大学学位论文著作权使用声明

本人同意厦门大学根据《中华人民共和国学位条例暂行实施办法》等规定保留和使用此学位论文，并向主管部门或其指定机构送交学位论文（包括纸质版和电子版），允许学位论文进入厦门大学图书馆及其数据库被查阅、借阅。本人同意厦门大学将学位论文加入全国博士、硕士学位论文共建单位数据库进行检索，将学位论文的标题和摘要汇编出版，采用影印、缩印或者其它方式合理复制学位论文。

本学位论文属于：

1. 经厦门大学保密委员会审查核定的保密学位论文，于 年 月 日解密，解密后适用上述授权。

2. 不保密，适用上述授权。

（请在以上相应括号内打“√”或填上相应内容。保密学位论文应是已经厦门大学保密委员会审定过的学位论文，未经厦门大学保密委员会审定的学位论文均为公开学位论文。此声明栏不填写的，默认为公开学位论文，均适用上述授权。）

声明人（签名）：

年 月 日

目 录

中文摘要.....	1
英文摘要.....	2
1 前言.....	4
1.1 胆管癌基础研究概况.....	4
1.1.1 胆管癌的分类.....	4
1.1.2 胆管癌的流行病学概况.....	5
1.1.3 胆管癌发生的高危因素.....	8
1.1.4 胆管癌发生的过程及分子生物学机制.....	8
1.1.5 胆管癌的临床症状及诊断.....	21
1.1.6 胆管癌的治疗.....	22
1.2 抗癌药物的筛选.....	24
1.2.1 药物筛选模型.....	24
1.2.2 抗癌药物的种类.....	26
1.2.3 抗癌药物作用的靶点.....	28
1.2.4 抗胆管癌药物研究现状.....	34
1.3 三苯氧胺在临床中的作用及作用机制.....	35
1.3.1 三苯氧胺在临床中的作用.....	35
1.3.2 三苯氧胺的作用机制.....	36
1.3.3 雌激素及其受体与胆管癌.....	44
1.4 蛋白质组学技术在胆管癌研究中的应用.....	45
1.5 本论文研究的内容和意义.....	46
2 实验试剂与仪器.....	48
2.1 主要材料和试剂.....	48
2.2 主要实验仪器.....	51
3 实验方法.....	53
3.1 药用植物的提取.....	53
3.2 河蚬的提取.....	53
3.3 肿瘤细胞的培养.....	53

3.4 MTT法测定细胞增殖率	54
3.5 细胞形态的观察	54
3.5.1 普通光学显微镜下细胞形态的观察.....	54
3.5.2 荧光显微镜下细胞形态的观察.....	55
3.5.3 透射电镜下细胞超微结构的观察.....	55
3.6 PI单染流式细胞术检测细胞周期变化	56
3.7 DNA抽提及琼脂糖凝胶电泳	56
3.8 FITC-Annexin V/PI双染流式细胞术	56
3.9 Caspase-3活性的测定	57
3.10 细胞内活性氧ROS的测定	57
3.11 Western blot	57
3.11.1 细胞的裂解.....	57
3.11.2 免疫印迹.....	58
3.12蛋白质组学技术方法	58
3.12.1 QBC939细胞全蛋白样品制备.....	58
3.12.2 等点聚焦电泳.....	58
3.12.3 SDS-PAGE电泳.....	58
3.12.4 考马斯亮蓝G-250染色.....	59
3.12.5 硝酸银染色.....	59
3.12.6 凝胶扫描和图像处理.....	59
3.12.7 差异蛋白点的胶内酶切与质谱分析.....	60
4 结果	61
4.1 抗胆管癌药物的筛选	61
4.1.1 药用植物提取物对体外培养的胆管癌QBC939细胞的作用.....	61
4.1.2 淡水贝类河蚬提取物对QBC939细胞增殖及细胞周期的影响.....	80
4.1.3 天然产物化合物对QBC939细胞增殖的影响.....	82
4.1.4 缩氨基硫脲类化合物对QBC939细胞增殖的影响.....	84
4.1.5 化疗药物对QBC939细胞增殖及细胞周期的影响.....	86
4.2 TAM抗胆管癌作用机制的研究	89
4.2.1 TAM对胆管癌细胞抑制作用的时间和剂量效应.....	89

4.2.2 TAM对不同肿瘤细胞敏感性的比较.....	90
4.2.3 TAM对胆管癌QBC939细胞形态学的影响.....	91
4.2.4 TAM对胆管癌细胞周期分布及细胞周期蛋白Cyclin D1的影响.....	96
4.2.5 TAM诱导胆管癌细胞凋亡.....	102
4.2.6 TAM激活Caspase-9和Caspase-3.....	104
4.2.7 凋亡相关蛋白对TAM诱导的胆管癌细胞凋亡作用的调控作用.....	106
4.2.8 胆管癌细胞中ER α 的表达及TAM作用后ER α 表达的变化.....	110
4.2.9 TAM作用后QBC939细胞内活性氧的变化情况.....	111
4.2.10 TAM对QBC939细胞内PKC α 蛋白表达的影响.....	113
4.2.11 TAM对QBC939细胞内C-Myc蛋白表达的影响.....	114
4.3 TAM作用后人胆管癌QBC939细胞全蛋白谱的差异表达变化.....	115
5 讨论.....	127
5.1 体外抗胆管癌药物的筛选.....	127
5.1.1 药用植物提取物对胆管癌细胞的影响.....	128
5.1.2 淡水贝类河蚬提取物对胆管癌细胞的影响.....	136
5.1.3 天然产物化合物对胆管癌细胞增殖的影响.....	137
5.1.4 缩氨基硫脲类化合物对胆管癌细胞增殖的影响.....	142
5.1.5 化疗药物对胆管癌细胞的影响.....	143
5.2 TAM体外抗胆管癌机制的研究.....	144
5.2.1 TAM对呈时间和剂量依赖性抑制QBC939细胞的增殖.....	144
5.2.2 胆管癌细胞较其他肿瘤细胞对TAM的作用更为敏感.....	144
5.2.3 TAM阻滞胆管癌细胞周期并诱导细胞凋亡.....	145
5.2.4 TAM下调胆管癌细胞中Cyclin D1蛋白的表达.....	146
5.2.5 TAM通过激活Caspase-9/Caspase-3诱导细胞凋亡.....	147
5.2.6 凋亡相关蛋白对TAM诱导的胆管癌细胞凋亡的调控.....	148
5.2.7 TAM能够抑制胆管癌QBC939细胞中ER α 的表达.....	149
5.2.8 TAM诱导胆管癌细胞凋亡的其他非ER途径.....	150
5.3 利用蛋白质组学技术研究TAM抗胆管癌作用的可能分子机制.....	152
5.3.1 热休克蛋白.....	154
5.3.2 细胞骨架蛋白.....	161

5.3.3 代谢相关酶和蛋白.....	163
5.3.4 膜联蛋白.....	166
6 结论.....	169
7 参考文献.....	171
在学期间发表论文.....	206
致谢.....	207

厦门大学博硕士论文摘要库

Contents

Abstract in Chinese	1
Abstract in English	2
1 Introduction	4
1.1 General introduction of cholangiocarcinoma	4
1.1.1 Classification.....	4
1.1.2 Epidemiology.....	5
1.1.3 Risk factors.....	8
1.1.4 Pathogenic process and molecular mechanism.....	8
1.1.5 Clinical features and diagnosis.....	21
1.1.6 Therapy.....	22
1.2 Screening of anticancer drugs	24
1.2.1 Model for drug screening.....	24
1.2.2 The type of anticancer drugs.....	26
1.2.3 Anticancer molecular targets.....	28
1.2.4 Present research situation of cholangiocarcinoma drugs.....	34
1.3 The effects of tamoxifen in clinic and the mechanisms	35
1.3.1 The effects of tamoxifen in clinic.....	35
1.3.2 Mechanisms of tamoxifen induced cell death.....	36
1.3.3 Estrogen, estrogen receptor and cholangiocarcinoma.....	44
1.4 Application of proteomics technology in study of cholangiocarcinoma	45
1.5 Contents and significance of this study	46
2 Reagents and instruments	48
2.1 Major reagents and materials	48
2.2 Major instruments	51
3 Methods	53
3.1 Extraction of medicinal plants	53
3.2 Extraction of <i>Corbicula fluminea</i>	53
3.3 Tumor cell culture	53

3.4 Cell survival rate determined by MTT assay	54
3.5 Observation of cell morphology	54
3.5.1 Observation of cell morphology by ordinary light microscope	54
3.5.2 Observation of cell morphology by fluorescence microscope	55
3.5.3 Observation of cell ultrastructure by transmission electron microscope	55
3.6 The changes of cell cycle determined by PI single staining flow cytometry .	56
3.7 DNA ladder assay	56
3.8 FITC-Annexin V/PI double staining flow cytometry	56
3.9 Caspase-3 activity assay	57
3.10 ROS activity assay	57
3.11 Western blot	57
3.11.1 Cell lysis.....	57
3.11.2 Immunoblot.....	58
3.12 Methods of proteomic	58
3.12.1 Preparation of total QBC939 cells proteome samples	58
3.12.2 IEF.....	58
3.12.3 SDS-PAGE electrophoresis.....	58
3.12.4 Coomassie brilliant blue staining.....	59
3.12.5 Silver staining.....	59
3.12.6 Scan and computer assisted 2-D image analysis.....	59
3.12.7 In gel digestion, analysis of MALDI-TOF-MS and database searches....	60
4 Results	61
4.1 Screening of cholangiocarcinoma drugs	61
4.1.1 Effect of the extracts from medicinal plants on QBC939 cells.....	61
4.1.2 Effect of the extracts from <i>Corbicula fluminea</i> on QBC939 cells.....	80
4.1.3 Effect of natural compounds on QBC939 cells.....	82
4.1.4 Effect of thiosemicarbazone compounds on QBC939 cells.....	84
4.1.5 Effect of chemotherapeutic drugs on QBC939 cells.....	86
4.2 Study on the anticancer mechanism of TAM in QBC939 cells	89
4.2.1 TAM inhibit the growth of cells in a time- and dose- dependent manner....	89

4.2.2 Compare on the sensitivity to different tumor cell lines of TAM.	90
4.2.3 Effect of TAM on the morphology of QBC939 cells.	91
4.2.4 Effect of TAM on cell cycle and the expression of Cyclin D1	96
4.2.5 TAM induced apoptosis in QBC939 cells.	102
4.2.6 Caspase-9 and Caspase-3 are activated by TAM.	104
4.2.7 Effect of apoptosis related proteins on TAM induced apoptosis.	106
4.2.8 The expression of ER α in QBC939 cells and the changes by TAM.	110
4.2.9 The changes of ROS by TAM in QBC939 cells.	111
4.2.10 The changes of the expression of PKC α by TAM in QBC939 cells.	113
4.2.11 The changes of the expression of C-Myc by TAM in QBC939 cells.	114
4.3 The effect of TAM on proteomic profile of QBC939 cells by proteomics technology.	115
5 Discussion.	127
5.1 Screening of cholangiocarcinoma drugs.	127
5.1.1 Effect of the extracts from medicinal plants on QBC939 cells.	128
5.1.2 Effect of the extracts from <i>Corbicula fluminea</i> on QBC939 cells.	136
5.1.3 Effect of natural compounds on QBC939 cells.	137
5.1.4 Effect of thiosemicarbazone compounds on QBC939 cells.	142
5.1.5 Effect of chemotherapeutic drugs on QBC939 cells.	143
5.2 Study on the anticancer mechanism of TAM in QBC939 cells <i>in vitro</i>.	144
5.2.1 TAM inhibit the growth of cells in a time- and dose- dependent manner. .	144
5.2.2 TAM is more sensitive to cholangiocarcinoma.	144
5.2.3 Cell cycle arrest and apoptosis induced by TAM.	145
5.2.4 Inhibition of the expression of Cyclin D1 by TAM.	146
5.2.5 Activation of Caspase-9 and Caspase-3 by TAM induced apoptosis.	147
5.2.6 Effect of apoptosis related proteins on TAM induced apoptosis.	148
5.2.7 Inhibit of the expression of ER α by TAM.	149
5.2.8 Other pathways induced by TAM in QBC939 cells.	150
5.3 The possible molecular mechanisms of anticancer effect of TAM on cholangiocarcinoma cells by proteomic technology.	152

5.3.1 Heat shock proteins.....	154
5.3.2 Cytoskeletal proteins.....	161
5.3.3 Metabolic related enzymes and proteins.....	163
5.3.4 Membrane associated protein.....	166
6 Conclusions.....	169
7 References.....	171
Publications.....	206
Acknowledgements.....	207

厦门大学博硕士学位论文摘要库

摘 要

胆管癌是一种难以治愈的恶性肿瘤。对于胆管癌的治疗，根治性手术是目前唯一有效的办法。但是，胆管癌的早期症状不明显、发现困难，一旦发现多数已进入晚期，很难通过手术方法切除，因此，寻找其他非手术方法治疗胆管癌就变得十分必要。目前临床应用的药物对胆管癌敏感性欠佳，而且存在明显毒副作用。因此，探索更敏感、有效的药物，提高胆管癌药物治疗的疗效就变得十分必要。

本论文以体外培养的人胆管癌 QBC939 细胞为药物筛选模型，选用叶下珠、珠子草、冬青、白英、长春花、三尖杉六种药用植物提取物、淡水贝类河蚬提取物、天然产物化合物、缩氨基硫脲类化合物及常见化疗药物，应用 MTT 测定法，从天然和化学合成物质中筛选具有抗胆管癌效应的药物。结果表明：珠子草和叶下珠的乙酸乙酯和正丁醇提取物、白英的水提物、长春花总碱、河蚬乙酸乙酯提取物、槲皮素、鞣酸、2-氯苯甲醛缩氨基硫脲、2, 4-二氯苯甲醛缩氨基硫脲和三苯氧胺等具有体外抗胆管癌细胞增殖的活性。

与胆管癌临床中常用的化疗药物 5-氟尿嘧啶和顺铂相比，三苯氧胺表现出了更强的抑制胆管癌细胞的作用。因此，本研究选择三苯氧胺（TAM）进行下一步的深入研究，探讨三苯氧胺体外抗胆管癌作用的机理。通过 MTT 法、细胞形态观察法、流式细胞术、DNA ladder 等方法研究表明：TAM 呈时间和剂量依赖性抑制胆管癌 QBC939 细胞的增殖、使细胞形态发生明显变化、使细胞周期阻滞于 G_0/G_1 期、且显著诱导细胞凋亡；通过 Western blot 等方法研究表明：TAM 对 Cyclin D1、ER α 、C-Myc 蛋白表达的抑制、Caspase-3/Caspase-9 信号通路的激活、Bax 和 p53 蛋白表达的上调，是 TAM 发挥抗胆管癌作用的部分机制。为了进一步的探讨 TAM 抗胆管癌作用的分子机制和药物作用靶点，我们首次应用蛋白质组学技术研究了三苯氧胺对人胆管癌 QBC939 细胞全蛋白表达谱的影响。最终成功鉴定出热休克蛋白、细胞骨架蛋白、膜联蛋白和代谢相关酶等差异表达的蛋白点。结合这些蛋白的功能，全面系统地分析了三苯氧胺抗胆管癌作用的可能的分子机制。为胆管癌的药物治疗提供了新的线索，为三苯氧胺在临床上应用于胆管癌的治疗提供了基础理论支持，也为三苯氧胺抗胆管癌作用新靶点的阐明提供了新的思路和线索。

关键词：胆管癌；药物筛选；三苯氧胺；机理；蛋白质组学

Abstract

Cholangiocarcinoma is a malignant tumor which is difficult to cure. At present, radical surgical removal represents the only curative treatment. However, the tumor often present at an advanced unresectable stage at the time of diagnosis for the majority patients, which eliminates the surgical approach as a curative measure. Thus, it is important to find out a effective therapeutic method excluded surgical. The response of cholangiocarcinoma to current clinical chemotherapeutic regimens is poor. The current clinical drugs for cholangiocarcinoma therapy often have toxic and side effects. Therefore, to improve the curative effect of drug therapy, it is urgent to find more sensitive and effective therapeutic drugs for cholangiocarcinoma.

In this study, cultured human cholangiocarcinoma cell line QBC939 *in vitro* was used as the model for drug screening. Extracts from *Phyllanthus niruri* L., *Phyllanthus urinaria* L., *Ilex chinensis* Sims, *Solanum lyratum* Thunb., *Catharanthus roseus*(L.) G. Don, *Cephalotaxus fortunei* Hook. f. which are medicinal plants and *Corbicula Fluminea* which is a kind of freshwater mollusk, natural compounds, thiosemicarbazone compounds and common chemotherapeutic drugs were selected to evaluate the growth inhibitory effects towards cholangiocarcinoma by MTT method. The results showed that ethyl acetate and butanol extracts from *Phyllanthus urinaria* L. and *Phyllanthus niruri* L., water extract from *Solanum lyratum* Thunb., Vinca alkaloids, ethyl acetate extract from *Corbicula Fluminea*, quercetin, tannic acid, 2-chlorobenzaldehyde thiosemicarbazone, 2,4-dichlorobenzaldehyde thiosemicarbazone and tamoxifen exhibit strong growth inhibitory effects toward cholangiocarcinoma cells.

Compared to 5-fluorouracil and cisplatin, tamoxifen was more sensitive to cholangiocarcinoma cells. Therefore, we did further studies to investigate the antitumor mechanisms of tamoxifen (TAM) on cholangiocarcinoma cells. By means of MTT method, morphologic observation method, flow cytometry, DNA ladder method and other methods, the results showed that TAM could significantly inhibit the growth of QBC939 cells in a time- and dose-dependent manner, change the morphology of

QBC939 cells, arrest the cell cycle at G₀/G₁ phase and induce apoptosis. By means of western blot and other methods, the results showed that inhibiting the expression of Cyclin D1, ER α , C-Myc, activation Caspase-3/Caspase-9 signal pathway and up-regulating the expression of Bax and p53 were considered to be the partial mechanisms. To understand the possible molecular mechanisms and function targets of inhibitory effect induced by TAM on cholangiocarcinoma cells, proteomics technology was first applied to investigate the effect of TAM on proteomic profile of QBC939 cells. Heat shock proteins, cytoskeletal proteins, membrane associated protein, metabolic related enzymes and other differential expression proteins were successfully identified. According to the functions of these proteins, we analysed the possible molecular anticancer mechanisms of TAM on cholangiocarcinoma cells comprehensive comprehensively and systematically. All our findings provide a new clue for the drug therapy of cholangiocarcinoma, provide theoretical support for application of TAM on cholangiocarcinoma therapy in clinic and provide new targets and strategies for elucidating the anticancer mechanisms of TAM on cholangiocarcinoma.

Key Words: Cholangiocarcinoma; Drug screening; Tamoxifen; Mechanisms; Proteomics.

Degree papers are in the "[Xiamen University Electronic Theses and Dissertations Database](#)". Full texts are available in the following ways:

1. If your library is a CALIS member libraries, please log on <http://etd.calis.edu.cn/> and submit requests online, or consult the interlibrary loan department in your library.
2. For users of non-CALIS member libraries, please mail to etd@xmu.edu.cn for delivery details.

厦门大学博硕士学位论文摘要库